References
Martin K (2017) Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep 12:389–396
Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C, Fabris F, Randi ML (2016) Thrombotic risk correlates with mutational status in true essential thrombocythemia. Eur J Clin Investig 46:683–689
Zerjavic K, Zagradisnik B, Stangler Herodez S, Lokar L, Glaser Krasevac M, Kokalj Vokac N (2010) Is the JAK2 V617F mutation a hallmark for different forms of thrombosis? Acta Haematol 124:49–56
Ianotto JC, Chauveau A, Luque Paz D, Delluc A, Tromeur C, Couturier MA, Gouillou M, Berthou C, Mottier D, Ugo V (2016) Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism. Thromb Haemost 115:225–226
Ianotto JC, Chauveau A, Mottier D, Ugo V, Berthou C, Lippert E, Delluc A (2017) JAK2 V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort. Ann Hematol 96:383–386
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study was performed in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from participants at the referring centres.
Conflict of interest
The author declares that he has no conflicts of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Langabeer, S.E. No indication for CALR mutation analysis in Irish patients presenting with deep vein thrombosis or pulmonary embolism. Ir J Med Sci 188, 1459–1460 (2019). https://doi.org/10.1007/s11845-019-02018-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-019-02018-3